Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity

被引:22
|
作者
Glazer, James [1 ]
Murray, Conor H. [2 ]
Nusslock, Robin [1 ]
Lee, Royce [2 ]
de Wit, Harriet [2 ]
机构
[1] Northwestern Univ, Dept Psychol, 2029 Sheridan Rd Evanston, Chicago, IL 60208 USA
[2] Univ Chicago, Dept Psychiat & Behav Neurosci, 5841 S Maryland Ave, Chicago, IL 60637 USA
基金
美国国家科学基金会;
关键词
SEROTONIN; DOPAMINE; MOOD; CONNECTIVITY; DEPRESSION; PSILOCYBIN; ANTIDEPRESSANTS; HALLUCINOGENS; ABNORMALITIES; ACTIVATION;
D O I
10.1038/s41386-022-01479-y
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Renewed interest in classic psychedelics as treatments for psychiatric disorders warrants a deeper understanding of their neural mechanisms. Single, high doses of psychedelic drugs have shown promise in treating depressive disorders, perhaps by reversing deficits in reward processing in the brain. In addition, there are anecdotal reports that repeated ingestion of low doses of LSD, or "microdosing", improve mood, cognition, and feelings of wellbeing. However, the effects of low doses of classic psychedelics on reward processing have not been studied. The current study examined the effects of two single, low doses of LSD compared to placebo on measures of reward processing. Eighteen healthy adults completed three sessions in which they received placebo (LSD-0), 13 mu g LSD (LSD-13) and 26 mu g LSD (LSD-26) in a within-subject, double-blind design. Neural activity was recorded while participants completed the electrophysiological monetary incentive delay task. Event-related potentials were measured during feedback processing (Reward-Positivity: RewP, Feedback-P3: FB-P3, and Late-Positive Potential: LPP). Compared to placebo, LSD-13 increased RewP and LPP amplitudes for reward (vs. neutral) feedback, and LSD-13 and LSD-26 increased FB-P3 amplitudes for positive (vs. negative) feedback. These effects were unassociated with most subjective measures of drug effects. Thus, single, low doses of LSD (vs. placebo) increased three reward-related ERP components reflecting increased hedonic (RewP), motivational (FB-P3), and affective processing of feedback (LPP). These results constitute the first evidence that low doses of LSD increase reward-related brain activity in humans. These findings may have important implications for the treatment of depressive disorders.
引用
收藏
页码:418 / 426
页数:9
相关论文
共 50 条
  • [1] Acute effects of lysergic acid diethylamide (LSD) on resting brain function
    Felix, Mueller
    Stefan, Borgwardt
    SWISS MEDICAL WEEKLY, 2019, 149
  • [2] The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity
    Bedford, Peter
    Hauke, Daniel J.
    Wang, Zheng
    Roth, Volker
    Nagy-Huber, Monika
    Holze, Friederike
    Ley, Laura
    Vizeli, Patrick
    Liechti, Matthias E.
    Borgwardt, Stefan
    Mueller, Felix
    Diaconescu, Andreea O.
    NEUROPSYCHOPHARMACOLOGY, 2023, 48 (08) : 1175 - 1183
  • [3] The paradoxical psychological effects of lysergic acid diethylamide (LSD)
    Carhart-Harris, R. L.
    Kaelen, M.
    Bolstridge, M.
    Williams, T. M.
    Williams, L. T.
    Underwood, R.
    Feilding, A.
    Nutt, D. J.
    PSYCHOLOGICAL MEDICINE, 2016, 46 (07) : 1379 - 1390
  • [4] Metabolism of lysergic acid diethylamide (LSD): an update
    Libanio Osorio Marta, Rui Filipe
    DRUG METABOLISM REVIEWS, 2019, 51 (03) : 378 - 387
  • [5] Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans
    Kanen, Jonathan W.
    Luo, Qiang
    Kandroodi, Mojtaba Rostami
    Cardinal, Rudolf N.
    Robbins, Trevor W.
    Nutt, David J.
    Carhart-Harris, Robin L.
    den Ouden, Hanneke E. M.
    PSYCHOLOGICAL MEDICINE, 2023, 53 (14) : 6434 - 6445
  • [6] D-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology
    De Gregorio, Danilo
    Comai, Stefano
    Posa, Luca
    Gobbi, Gabriella
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (11)
  • [7] Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience
    Omidian, Hossein
    Omidian, Alborz
    PHARMACEUTICALS, 2025, 18 (04)
  • [8] Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
    Family, Neiloufar
    Maillet, Emeline L.
    Williams, Luke T. J.
    Krediet, Erwin
    Carhart-Harris, Robin L.
    Williams, Tim M.
    Nichols, Charles D.
    Goble, Daniel J.
    Raz, Shlomi
    PSYCHOPHARMACOLOGY, 2020, 237 (03) : 841 - 853
  • [9] Oxidation of lysergic acid diethylamide (LSD) by peroxidases: a new metabolic pathway
    Gomes, Melissa M.
    Doerr, Felipe A.
    Catalani, Luiz H.
    Campa, Ana
    FORENSIC TOXICOLOGY, 2012, 30 (02) : 87 - 97
  • [10] Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
    Krebs, Teri S.
    Johansen, Pal-Orjan
    JOURNAL OF PSYCHOPHARMACOLOGY, 2012, 26 (07) : 994 - 1002